Santhera Pharmaceuticals Holding AG (XSWX:SANN) ROCE % : -770,150.00% (As of Jun. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Santhera Pharmaceuticals Holding AG ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Santhera Pharmaceuticals Holding AG's annualized ROCE % for the quarter that ended in Jun. 2023 was -770,150.00%.

Santhera Pharmaceuticals Holding AG ROCE % Historical Data

The historical data trend for Santhera Pharmaceuticals Holding AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santhera Pharmaceuticals Holding AG ROCE % Chart

Santhera Pharmaceuticals Holding AG Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-52.76

-13.55

-80.38

-64.93

-138.83

Santhera Pharmaceuticals Holding AG Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
ROCE %	Get a 7-Day Free Trial															-37.43	-125.19	-83.50	-213.62	-770,150.00

Santhera Pharmaceuticals Holding AG ROCE % Calculation

Santhera Pharmaceuticals Holding AG's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-50.427	/	( ( (91.117 - 32.782)	+	(63.726 - 49.414) )	/ 2 )
	=	-50.427	/	( (58.335	+	14.312)	/ 2 )
	=	-50.427	/	36.3235
	=	-138.83 %

Santhera Pharmaceuticals Holding AG's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	-30.806	/	( ( (63.726 - 49.414)	+	(63.075 - 77.379) )	/ 2 )
	=	-30.806	/	( ( 14.312	+	-14.304 )	/ 2 )
	=	-30.806	/	0.0039999999999978
	=	-770,150.00 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

Santhera Pharmaceuticals Holding AG (XSWX:SANN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Santhera Pharmaceuticals Holding AG ROCE % Related Terms

Thank you for viewing the detailed overview of Santhera Pharmaceuticals Holding AG's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Santhera Pharmaceuticals Holding AG (XSWX:SANN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Santhera Pharmaceuticals Holding AG (XSWX:SANN) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

SPHDF:USA SANNz:UK

Address

Hohenrainstrasse 24, Pratteln, CHE, 4133

Website

https://www.santhera.com

Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area that includes many orphan and niche indications with high unmet medical needs. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary, and neuromuscular diseases. The company derives most of its revenue from the European Union.

Santhera Pharmaceuticals Holding AG (XSWX:SANN) Headlines

No Headlines